CNST - Constellation Pharmaceuticals: An Exciting Mid-Stage Oncology Player For 2020
Today, we will see why Constellation Pharmaceuticals (CNST) is an attractive pick for 2020.
Company overview
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on deploying epigenetics for the development of therapies targeting cancers associated with abnormal gene expression. The company is developing small molecule therapies that selectively modulate gene expression in tumors and tumor microenvironments for cell apoptosis. Besides, the company is also using epigenetics to increase anti-tumor activity in immune cells. Constellation Pharmaceuticals is also leveraging the power of biomarkers to target populations most likely to benefit from these epigenetic interventions.